Skip to Main Content

Paper Details

Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers.
PLoS One
20
2015
E/GEJ adenocarcinoma, E/GEJ adenocarcinoma xenograft lines, EGFR, GEJ cancers, Her-2, Ki-67, PTXGs, Tumors, esophageal (E) and gastro-esophageal junction (GEJ) cancers, esophageal adenocarcinoma, esophageal/gastro-esophageal junction cancers, human, human E, mRNA, mice, neu, p16, p53, patient, patients, primary esophageal adenocarcinoma xenograft lines, primary tumor, primary tumor xenografts, stroma, tumor, tumors, xenograft, xenografts
Animals, Esophageal Neoplasms, Esophagogastric Junction, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Stomach Neoplasms, Xenograft Model Antitumor Assays
Author NameAffiliation
Lorin DodbibaUniversity of Toronto, Canada Wayne State University
Jennifer TeichmanUniversity of Toronto
Andrew FleetOntario Cancer Institute
Henry ThaiUniversity Health Network, Princess Margaret Hospital
Maud H W StarmansOntario Institute for Cancer Research, Maastricht University Medical Center
Roya NavabOntario Cancer Institute
Zhuo ChenUniversity of Toronto
Hala GirgisToronto General Hospital
Lawson EngOntario Cancer Institute
Osvaldo Espin-GarciaOntario Institute for Cancer Research
Xiaowei ShenOntario Institute for Cancer Research
Bizhan BandarchiOntario Cancer Institute
Joerg SchwockToronto General Hospital
Ming-Sound TsaoOntario Cancer Institute, Canada University Health Network, Princess Margaret Hospital, Toronto General Hospital
Hala El-ZimaityUniversity Health Network, Princess Margaret Hospital, Toronto General Hospital
Sandy D DerOntario Cancer Institute
Wei XuPrincess Margaret Hospital, Ontario Institute for Cancer Research
Robert G BristowUniversity of Toronto, Canada Ontario Cancer Institute
Gail DarlingToronto General Hospital
Paul C BoutrosUniversity of Toronto, Ontario Institute for Cancer Research
Laurie AillesUniversity of Toronto, Canada Ontario Cancer Institute
Geoffrey LiuUniversity of Toronto, Canada Ontario Cancer Institute, Dalla Lana School of Public Health
  • 1 - 22

Datasets

Release 1.2